Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study
- Conditions
- Ischemic Stroke
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- ReNeuron Limited
- Target Recruit Count
- 9
- Registration Number
- NCT05598775
- Locations
- 🇺🇸
Amy Miller, RPh, PharmD, Morgantown, West Virginia, United States
Investigation of Neural Stem Cells in Ischemic Stroke
- Conditions
- Ischemic StrokeChronic StrokeHemiparesisArm Paralysis
- Interventions
- Combination Product: CTX0E03 Drug Product and delivery deviceDrug: Placebo
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- ReNeuron Limited
- Target Recruit Count
- 15
- Registration Number
- NCT03629275
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸University of California, Irvine, Irvine, California, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
An Ischaemic Stroke Observational Study
- Conditions
- Stroke
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- ReNeuron Limited
- Target Recruit Count
- 39
- Registration Number
- NCT03333980
- Locations
- 🇬🇧
New Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Ninewells Hospital & Medical School, Dundee, United Kingdom
🇬🇧Queen Elizabeth University Hospital., Glasgow, United Kingdom
Safety and Tolerability of hRPC in Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: hRPC
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- ReNeuron Limited
- Target Recruit Count
- 29
- Registration Number
- NCT02464436
- Locations
- 🇺🇸
Retinal Research Institute, Phoenix, Arizona, United States
🇺🇸Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Pilot Investigation of Stem Cells in Stroke Phase II Efficacy
- Conditions
- HemiparesisIschaemic StrokeArm ParalysisCerebral Infarction
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- ReNeuron Limited
- Target Recruit Count
- 23
- Registration Number
- NCT02117635
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧NHS Southern General Hospital, Glasgow, United Kingdom
🇬🇧Kings College Hospital, London, United Kingdom
- Prev
- 1
- 2
- Next